- Home
- KUKE vs CNTX Comparison
KUKE vs CNTX Comparison
Compare KUKE & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KUKE
- CNTX
- Stock Information
- Founded
- KUKE 2002
- CNTX 2015
- Country
- KUKE China
- CNTX United States
- Employees
- KUKE N/A
- CNTX N/A
- Industry
- KUKE Other Consumer Services
- CNTX Biotechnology: Pharmaceutical Preparations
- Sector
- KUKE Real Estate
- CNTX Health Care
- Exchange
- KUKE Nasdaq
- CNTX Nasdaq
- Market Cap
- KUKE 86.8M
- CNTX 78.0M
- IPO Year
- KUKE 2021
- CNTX 2021
- Fundamental
- Price
- KUKE $2.62
- CNTX $0.84
- Analyst Decision
- KUKE
- CNTX Strong Buy
- Analyst Count
- KUKE 0
- CNTX 5
- Target Price
- KUKE N/A
- CNTX $5.50
- AVG Volume (30 Days)
- KUKE 9.5K
- CNTX 197.0K
- Earning Date
- KUKE 08-05-2025
- CNTX 08-06-2025
- Dividend Yield
- KUKE N/A
- CNTX N/A
- EPS Growth
- KUKE N/A
- CNTX N/A
- EPS
- KUKE N/A
- CNTX N/A
- Revenue
- KUKE $9,442,397.00
- CNTX N/A
- Revenue This Year
- KUKE N/A
- CNTX N/A
- Revenue Next Year
- KUKE N/A
- CNTX N/A
- P/E Ratio
- KUKE N/A
- CNTX N/A
- Revenue Growth
- KUKE N/A
- CNTX N/A
- 52 Week Low
- KUKE $1.45
- CNTX $0.49
- 52 Week High
- KUKE $17.50
- CNTX $2.75
- Technical
- Relative Strength Index (RSI)
- KUKE 29.13
- CNTX 64.84
- Support Level
- KUKE $2.58
- CNTX $0.82
- Resistance Level
- KUKE $2.96
- CNTX $0.87
- Average True Range (ATR)
- KUKE 0.14
- CNTX 0.07
- MACD
- KUKE -0.03
- CNTX 0.01
- Stochastic Oscillator
- KUKE 20.63
- CNTX 58.27
About KUKE Kuke Music Holding Limited
Kuke Music Holding Ltd provides classical music licensing, subscription, and education services in China. The company licenses its music content to online music entertainment platforms, such as Tencent Music Entertainment Group, digital music service providers, such as NetEase Cloud Music, as well as film and TV production companies, airlines, and smart hardware companies. Users can access the platform through the website, mobile app, and smart music devices.
About CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.